PMID: 9191875May 1, 1997Paper

Intratumoral infusion of the monoclonal antibody, mAb 425, against the epidermal-growth-factor receptor in patients with advanced malignant glioma

Cancer Immunology, Immunotherapy : CII
P WersällJ Boethius

Abstract

Malignant glioblastoma may over-express the epidermal-growth-factor receptor (EGF-R). Normal brain cells show a low or no expression of EGF-R. A mouse monoclonal antibody (IgG2A) (mAb 425) (EMD55900) (Merck KGaA, Bernstadt, Germany) directed against EGF-R was produced for therapeutic use. Eight patients with primary or recurrent, EGF-R-positive glioblastomas entered the study, which was designed to evaluate the clinical effect of the mAb. In order to achieve a high tumor cell saturation, the mAb was injected intratumorally twice weekly through an implantable catheter. The total administered dose varied between 4 mg and 120 mg. In 3 patients with solid tumors, a massive tumor necrosis was noted, with infiltration of macrophages, granulocytes and T cells. A further 3 patients developed clinical and radiological signs of an intense, local, inflammatory reaction. There may be a relation between the mAb dosage and the antitumor effect, insofar as higher doses seemed to cause a more pronounced, inflammatory reaction. Of the 8 patients, 6 developed human, anti-(mouse Ig) antibodies. This anti-EGF-R mAb may induce an intense, inflammatory reaction and a considerable necrosis in glioblastoma. However, the planned schedule could not be c...Continue Reading

Citations

Apr 6, 2001·International Journal of Cancer. Journal International Du Cancer·S R HusainR K Puri
Feb 22, 2002·International Journal of Cancer. Journal International Du Cancer·Olav EngebraatenOystein Fodstad
Mar 26, 2008·Current Treatment Options in Oncology·Sunit DasKenji Muro
Dec 6, 2001·Current Oncology Reports·Shanu Modi, Andrew D Seidman
Aug 26, 1998·FEBS Letters·K M MüllerA Plückthun
Aug 24, 1999·Pharmacology & Therapeutics·J R Woodburn
May 21, 1998·Nature Biotechnology·W DebinskiR K Puri
Feb 18, 2003·Journal of Internal Medicine·P Nygren, R Larsson
Mar 31, 2001·Cancer Biotherapy & Radiopharmaceuticals·T CrombetA Lage
Feb 10, 2000·Annals of the New York Academy of Sciences·D T Curiel
Apr 28, 2011·Neurosurgery·Yan Michael Li, Walter A Hall
Mar 6, 2012·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Mette K NedergaardHans S Poulsen
Feb 25, 2005·Neurosurgical Focus·Walter A HallAnthony L Asher
Sep 29, 2004·Child's Nervous System : ChNS : Official Journal of the International Society for Pediatric Neurosurgery·Steven De VleeschouwerFrank Van Calenbergh
Mar 20, 1999·Current Opinion in Pediatrics·J B Rubin, M W Kieran
Oct 17, 2009·Expert Review of Neurotherapeutics·Waldemar Debinski, Stephen B Tatter
Mar 21, 2007·Expert Opinion on Investigational Drugs·David E Gerber, John Laterra
Jun 23, 2009·Expert Opinion on Drug Delivery·Jill M Stukel, Michael R Caplan
Apr 28, 2006·Expert Opinion on Drug Delivery·Walter A Hall, Gregory T Sherr
Sep 1, 2004·Expert Opinion on Biological Therapy·Abraham BoskovitzDarell D Bigner
Aug 29, 2002·Cancer Investigation·Waldemar Debinski
Jun 24, 2014·Journal of Controlled Release : Official Journal of the Controlled Release Society·Xiang YiAlexander V Kabanov
Jul 4, 2012·Neurosurgery Clinics of North America·Seunggu J HanAndrew T Parsa
Dec 1, 2009·Neurosurgery Clinics of North America·Seunggu J HanMichael Lim
Sep 12, 2009·Brain Pathology·Stefaan Van GoolSteven De Vleeschouwer
Nov 3, 2004·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·Andrew P Morokoff, Ulrike Novak
Mar 10, 2015·Neuro-oncology·Michael A Vogelbaum, Manish K Aghi
Dec 17, 2016·Neurologia Medico-chirurgica·Ryuta Saito, Teiji Tominaga
Aug 24, 1999·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·D W MoraesC R Carneiro
Jun 16, 2009·Cell Transplantation·Der-Yang ChoShih-Ping Liu
Dec 17, 1997·International Journal of Cancer. Journal International Du Cancer·P WersällH Mellstedt
Jan 28, 2005·Journal of Neuro-oncology·Manfred Westphal, Peter McL Black
Jul 19, 2016·Expert Review of Proteomics·Rebecca Christine Feiner, Kristian Mark Müller
Sep 4, 2003·Journal of Neuro-oncology·Edward RustamzadehWalter A Hall
Jul 7, 2017·Current Treatment Options in Oncology·Jaclyn J RenfrowGlenn J Lesser
Oct 22, 2019·Frontiers in Oncology·Caleb A Stine, Jennifer M Munson
Jun 27, 2019·International Journal of Cancer. Journal International Du Cancer·Julien FleurenceStéphane Birklé
Aug 21, 2019·Journal of Oncology·Minghan Shi, Léon Sanche
Feb 19, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Alba A BrandesRoger Stupp

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
G StragliottoJ Y Delattre
European Archives of Oto-rhino-laryngology : Official Journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : Affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
H BierP Stasiecki
© 2021 Meta ULC. All rights reserved